Jason Mast is a reporter at STAT focused on the science behind new medicines and the systems that determine their accessibility to patients. His work spans various aspects of medicine and healthcare, including pharmaceuticals, healthcare technology, and alternative medicine. Jason has been featured in prominent publications such as Endpoints News, RamaOnHealthcare, STAT News, and The Boston Globe.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Jason Mast's primary focus is on healthcare, pharmaceuticals, and scientific advancements in the field. His articles tend to cite data and press releases heavily, indicating a preference for fact-based reporting.
When reaching out to Jason, consider offering insights from experts in the fields of CRISPR technology, gene therapy, pharmaceuticals industry trends, or specific diseases being discussed. Additionally, he may be interested in government announcements related to healthcare policies or regulations impacting these areas.
As there is no specified geographic focus for Jason's coverage area; therefore global perspectives on relevant topics would likely be appreciated.
This information evolves through artificial intelligence and human feedback. Improve this profile .
In Q&A, Chien predicts mRNA cancer vaccine will reshape oncology and ‘raise all boats'
Bluebird Bio was a dark biotech morality tale when David Meek bought it. He says the new company, Genetix, is already making money.
By: Jason Mast
This story is republished from STAT , the health and medicine news site that's a partner to the Globe. Sign up for STAT's free Morning Rounds newsletter here
By: Jason Mast
Hong Kong-based Sino Biopharm strikes a pair of deals for respiratory drugs Good morning, Jason Mast here filling in for the one and only Ed Silverman.
By: Jason Mast
Prime Medicine said Wednesday that it had won an arbitration dispute against Beam Therapeutics, resolving for now a clash that had pitted two well-backed gene-editing companies that had been spun out of the same lab against each other.
By: Matthew Herper, Jason Mast
How a father’s quest may shape the future of rare disease gene therapy.
By: Jason Mast
Moderna has won an EU contract to supply RSV vaccines to six countries Good morning, Jason Mast here filling in for Ed Silverman again.
Program will fund seven groups over five years in hope of Baby KJ-like successes
Program will fund seven groups over five years in hope of Baby KJ-like successesARPA-H, the U.S.’ “moonshot” agency for health research, announced
By: Jason Mast, Matthew Herper
A father's $70 million pursuit of a gene therapy has implications for an entire field Highlights
